Multigene tests for breast cancer: the physician's perspective.

adjuvant chemotherapy adjuvant hormone therapy breast cancer genomic tests

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
27 Apr 2021
Historique:
received: 03 11 2020
accepted: 01 04 2021
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 7 5 2021
Statut: epublish

Résumé

Breast cancer is the most common tumour in women and the first cause of death for cancer in the female population. Preserving the quality of life has therefore become an important objective in the management of the disease. The benefits of adjuvant chemotherapy in patients with HR+ HER2- early breast cancer should always be balanced against its potential short and long-term adverse effects, and identifying the appropriate patients for whom chemotherapy can offer the highest clinical benefit is critical. Besides clinical and pathological factors, today four multigene tests able to guide the choice of the adjuvant therapy early breast cancer are available in Italy: Oncotype DX

Identifiants

DOI: 10.18632/oncotarget.27948 PMID: 33953847 PMC: PMC8092339
pubmed: 33953847
doi: 10.18632/oncotarget.27948
pii: 27948
pmc: PMC8092339
doi:

Types de publication

Journal Article

Langues

eng

Pagination

936-947

Informations de copyright

Copyright: © 2021 Cognetti et al.

Déclaration de conflit d'intérêts

CONFLICTS OF INTEREST Sandro Barni received honoraria from Roche, Italfarmaco, Eisai, Mylan, Leo Pharma, Genomic Health, Pharmanutra, Kyowa Kyrin. Laura Biganzoli received honoraria from AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre, Roche and has institutional financial interests with Celgene, Genomic Health, Novartis. Carlo Alberto Tondini received honoraria from Genomic Health/Exact Science and Myriad; reasearch grants from Genomic Health. Giuseppe Tonini received honoraria from Molteni, Novartis, Pharmamar, Lilly. All the other Authors have no conflicts of interest to declare.

Références

JAMA Oncol. 2018 Apr 1;4(4):545-553
pubmed: 29450494
Bone Marrow Transplant. 2005 Aug;36(3):251-9
pubmed: 15937502
Cancer Treat Rev. 2018 Jan;62:74-90
pubmed: 29175678
N Engl J Med. 2015 Nov 19;373(21):2005-14
pubmed: 26412349
Cancer J. 2011 Nov-Dec;17(6):500-4
pubmed: 22157294
Ann Oncol. 2011 Sep;22(9):1939-1947
pubmed: 21289366
NPJ Breast Cancer. 2017 Sep 8;3:33
pubmed: 28900633
Lancet Oncol. 2003 Apr;4(4):251-4
pubmed: 12681269
Eur J Surg Oncol. 2017 May;43(5):909-920
pubmed: 27639633
J Natl Cancer Inst Monogr. 2001;(30):135-42
pubmed: 11773307
J Natl Cancer Inst. 2016 Apr 29;108(9):
pubmed: 27130929
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
NPJ Breast Cancer. 2017 Sep 8;3:32
pubmed: 28900632
J Clin Oncol. 2008 Feb 10;26(5):721-8
pubmed: 18258979
J Clin Oncol. 2004 May 1;22(9):1630-7
pubmed: 15117985
J Clin Oncol. 2016 Jul 10;34(20):2341-9
pubmed: 26926676
Clinicoecon Outcomes Res. 2018 Mar 19;10:189-199
pubmed: 29593426
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
Cancer. 1995 Dec 1;76(11):2266-74
pubmed: 8635031
Nature. 2002 Jan 31;415(6871):530-6
pubmed: 11823860
Breast. 2015 Nov;24 Suppl 2:S149-53
pubmed: 26299406
J Clin Oncol. 2019 Aug 1;37(22):1956-1964
pubmed: 31150316
Curr Opin Oncol. 2019 Jan;31(1):29-34
pubmed: 30299292
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
CMAJ. 2005 Sep 27;173(7):765-71
pubmed: 16186583
Lancet. 2011 Nov 19;378(9805):1812-23
pubmed: 22098854
Ann Oncol. 2019 Oct 1;30(10):1541-1557
pubmed: 31373601
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
Breast Cancer Res. 2014 Apr 12;16(2):R38
pubmed: 24725534
Breast Cancer Res Treat. 2017 Oct;165(3):573-583
pubmed: 28664507
J Clin Oncol. 2018 Feb 20;36(6):554-562
pubmed: 29309250
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Breast. 2018 Feb;37:89-98
pubmed: 29128582
Eur J Breast Health. 2017 Oct 01;13(4):168-174
pubmed: 29082373
Am J Manag Care. 2017 Dec 1;23(12):e416-e420
pubmed: 29261249
Breast Cancer Res Treat. 2009 Jul;116(2):295-302
pubmed: 18661261
CA Cancer J Clin. 2006 May-Jun;56(3):168-83
pubmed: 16737949
Clin Cancer Res. 2011 Sep 15;17(18):6012-20
pubmed: 21807638
J Natl Cancer Inst. 2016 Jul 10;108(11):
pubmed: 27400969

Auteurs

Francesco Cognetti (F)

Scuola di specializzazione di Oncologia, La Sapienza University, Rome, Italy.

Laura Biganzoli (L)

Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.

Sabino De Placido (S)

Università Degli Studi di Napoli Federico II Dipartimento di Medicina clinica e Chirurgia Professore di Oncologia Medica, Napoli, Italy.

Lucia Del Mastro (L)

Oncology, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca del Cancro, Genova, Italy.

Riccardo Masetti (R)

Breast Center, Catholic University, Rome, Italy.

Giuseppe Naso (G)

Department of Radiology, Pathology and Oncology, La Sapienza University, Rome, Italy.

Giancarlo Pruneri (G)

Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Donatella Santini (D)

Department of Pathology, IRCCS Azienda Ospedaliera Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Italy.

Carlo Alberto Tondini (CA)

Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Corrado Tinterri (C)

Senology Unit, Humanitas Cancer Center, Rozzano, Milan, Italy.

Giuseppe Tonini (G)

Medical Oncology, School University Campus Bio-Medico, Rome, Italy.

Sandro Barni (S)

Emeritus, Department of Oncology, ASST Bergamo Ovest, Treviglio, Bergamo, Italy.

Classifications MeSH